Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Bevacizumab in Stage IIIB and IV BAC and ADENOBAC
NCT00436332Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Jul 2007
- Primary completion
- Jul 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in bronchioloalveolar carcinoma (BAC) and Adenocarcinoma, sponsored by SWOG Cancer Research Network. Primary endpoint: Overall Survival at 3 years. Started Jul 2007; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
bronchioloalveolar carcinoma (BAC)Adenocarcinoma
Beyond the preview
Go deeper on NCT00436332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00436332.